Background Denosumab is a human monoclonal antibody (mAb) that specifically inhibits
tumor-associated bone lysis through the RANKL pathway and has been used as …

Background Physiological bone formation and bone regeneration occurring during bone
repair can be considered distinct but similar processes. Mesenchymal stem cells (MSC) and …

Background Denosumab, a monoclonal antibody that binds to receptor activation of nuclear
factor-kappa ß ligand (RANKL), has been used as a drug to treat aggressive giant cell …

Background Giant cell tumor of bone (GCTB) in distal radius is a benign but invasive bone
tumor characterized by strong aggressive behavior and frequent recurrence. Methods To …

Background En bloc excision has been increasingly used for the management of giant cell
tumors (GCTs) in the distal radius. An osteoarticular allograft has been used extensively for …

Background Giant cell tumor of the bone (GCT) has high local recurrence rates and the
prognosis is hard to predict. We therefore retrospectively analyzed clinical outcome and …

Giant cell tumor of bone (GCTB) is a biologically benign and locally aggressive tumor that
most often affects the epiphyseal and metaphyseal sites of long bones in the young adult …

Giant-cell tumor of bone is a rare, locally aggressive and rarely metastasizing primary bone
tumor. The mainstay of treatment remains controversial and is decided by the balance …

Metastatic bone cancer pain may cause significant morbidity among the cancer patient
population. Painful bone lesions are challenging to manage due to the aggressive …

Background Giant cell tumor of bone (GCTB) is a primary bone tumor which comprises giant
cells and two types of stromal cells. Recent studies have suggested therapeutic risks of …